Acadia wins Delaware court ruling on Nuplazid '721 patent; signs new Princeton lease
On May 16, 2025, a U.S. District Court in Delaware ruled in Acadia's favor on both infringement and validity in its '721 formulation patent case over Nuplazid (pimavanserin) against Aurobindo and MSN. The same week, Acadia agreed to a 12-year, two-month lease for about 52,771 square feet in Princeton, New Jersey, and will end its current 502 Carnegie Center lease after the new lease begins.
Key points
- Court ruling date: May 16, 2025, in the U.S. District Court for the District of Delaware, covering both infringement and validity arguments
- Defendants in the patent case: Aurobindo Pharma Limited and its affiliate, and MSN Laboratories Private Ltd. and its affiliate
- 210 Lease: about 52,771 square feet, term of 12 years and 2 months, commencing no later than January 1, 2026, with first-year payment of $1,899,756
- Maximum landlord contribution of $5,277,100 for improvements, with a possible $2,638,550 supplemental contribution repayable with 8.00% interest
The filing
Written by AI on Nov 8, 2026, 1:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 20, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.